Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the presentation of long-term data demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) show the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event October 28, 2016 7:54 AM Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CFOctober 27, 2016 8:53 AM